File this under “When is a bargain not really a bargain?”

Three months ago, the Food and Drug Administration approved a generic version of the EpiPen allergy-relief device and made a point of noting the new product from Teva Pharmaceutical (TEVA) would offer a “lower-cost option.” But Teva is not offering the sort of alternative the agency envisioned: Its $300 list price is the same that Mylan (MYL) charges for its so-called authorized generic EpiPen.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What they really need is an epi-pen with a new design. The current one is too large and awkwardly shaped to carry in your pocket without looking a bit too “happy” to see everyone 🙁

    • Auvi-Q from kaleo has a great alternative form factor. Carried in a pocket, it would look like a flip phone. Also, it will talk someone through how to use the device, in case the user is incapacitated.

      I have no interest in the company/product other than it is what my daughter carries and has had to use once. She even got to train the local EMT/fire department on the device after they showed up at her school.

  • May I observe that, strictly speaking, the TEVA offering is cheaper than “the EpiPen?” We shall see what impact a third entrant will cause … when there is one.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy